181 related articles for article (PubMed ID: 8297715)
21. Sensitivity to 5,10-dideazatetrahydrofolate is fully conserved in a murine leukemia cell line highly resistant to methotrexate due to impaired transport mediated by the reduced folate carrier.
Zhao R; Gao F; Babani S; Goldman ID
Clin Cancer Res; 2000 Aug; 6(8):3304-11. PubMed ID: 10955817
[TBL] [Abstract][Full Text] [Related]
22. Phase I study of (6R)-5,10-dideazatetrahydrofolate: a folate antimetabolite inhibitory to de novo purine synthesis.
Ray MS; Muggia FM; Leichman CG; Grunberg SM; Nelson RL; Dyke RW; Moran RG
J Natl Cancer Inst; 1993 Jul; 85(14):1154-9. PubMed ID: 8320744
[TBL] [Abstract][Full Text] [Related]
23. A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid.
Laohavinij S; Wedge SR; Lind MJ; Bailey N; Humphreys A; Proctor M; Chapman F; Simmons D; Oakley A; Robson L; Gumbrell L; Taylor GA; Thomas HD; Boddy AV; Newell DR; Calvert AH
Invest New Drugs; 1996; 14(3):325-35. PubMed ID: 8958188
[TBL] [Abstract][Full Text] [Related]
24. Mechanism of the induction of the differentiation of HL-60 leukemia cells by antifolates.
Sokoloski JA; Beardsley GP; Sartorelli AC
Cancer Commun; 1989; 1(3):199-207. PubMed ID: 2700913
[TBL] [Abstract][Full Text] [Related]
25. The enhancement of the activity of 10-propargyl-5,8-dideazafolate and 5,10-dideazatetrahydrofolate by inhibitors of dihydrofolate reductase.
Galivan J; Rhee MS; Johnson TB; Chou TC; Nair MG; Bunni M; Priest D
Adv Enzyme Regul; 1989; 28():13-21. PubMed ID: 2624172
[TBL] [Abstract][Full Text] [Related]
26. Structural features of 5,10-dideaza-5,6,7,8-tetrahydrofolate that determine inhibition of mammalian glycinamide ribonucleotide formyltransferase.
Baldwin SW; Tse A; Gossett LS; Taylor EC; Rosowsky A; Shih C; Moran RG
Biochemistry; 1991 Feb; 30(7):1997-2006. PubMed ID: 1993209
[TBL] [Abstract][Full Text] [Related]
27. Growth-inhibitory effects of 5,10-dideazatetrahydrofolic acid on variant murine L1210 and human CCRF-CEM leukemia cells with different membrane-transport characteristics for (anti)folate compounds.
Jansen G; Westerhof GR; Kathmann I; Rijksen G; Schornagel JH
Cancer Chemother Pharmacol; 1991; 28(2):115-7. PubMed ID: 2060081
[TBL] [Abstract][Full Text] [Related]
28. Antifolate drug interactions: enhancement of growth inhibition due to the antipurine 5,10-dideazatetrahydrofolic acid by the lipophilic dihydrofolate reductase inhibitors metoprine and trimetrexate.
Galivan J; Nimec Z; Rhee M; Boschelli D; Oronsky AL; Kerwar SS
Cancer Res; 1988 May; 48(9):2421-5. PubMed ID: 2965613
[TBL] [Abstract][Full Text] [Related]
29. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity.
Westerhof GR; Schornagel JH; Kathmann I; Jackman AL; Rosowsky A; Forsch RA; Hynes JB; Boyle FT; Peters GJ; Pinedo HM
Mol Pharmacol; 1995 Sep; 48(3):459-71. PubMed ID: 7565626
[TBL] [Abstract][Full Text] [Related]
30. Increased thymidylate synthase in L1210 cells possessing acquired resistance to N10-propargyl-5,8-dideazafolic acid (CB3717): development, characterization, and cross-resistance studies.
Jackman AL; Alison DL; Calvert AH; Harrap KR
Cancer Res; 1986 Jun; 46(6):2810-5. PubMed ID: 2938731
[TBL] [Abstract][Full Text] [Related]
31. Accumulation of DNA strand breaks in cells exposed to methotrexate or N10-propargyl-5,8-dideazafolic acid.
Lorico A; Toffoli G; Boiocchi M; Erba E; Broggini M; Rappa G; D'Incalci M
Cancer Res; 1988 Apr; 48(8):2036-41. PubMed ID: 3349474
[TBL] [Abstract][Full Text] [Related]
32. Dipyridamole potentiates antipurine antifolate activity in the presence of hypoxanthine in tumor cells but not in normal tissues in vitro.
Marshman E; Newell DR; Calvert AH; Dickinson AM; Patel HR; Campbell FC; Curtin NJ
Clin Cancer Res; 1998 Nov; 4(11):2895-902. PubMed ID: 9829758
[TBL] [Abstract][Full Text] [Related]
33. Augmentation of the therapeutic activity of lometrexol -(6-R)5,10-dideazatetrahydrofolate- by oral folic acid.
Alati T; Worzalla JF; Shih C; Bewley JR; Lewis S; Moran RG; Grindey GB
Cancer Res; 1996 May; 56(10):2331-5. PubMed ID: 8625328
[TBL] [Abstract][Full Text] [Related]
34. Antitumor activity of antifolate inhibitors of thymidylate and purine synthesis in human soft tissue sarcoma cell lines with intrinsic resistance to methotrexate.
Li WW; Tong WP; Bertino JR
Clin Cancer Res; 1995 Jun; 1(6):631-6. PubMed ID: 9816025
[TBL] [Abstract][Full Text] [Related]
35. 7-Hydroxymethotrexate cytotoxicity and selectivity in a human Burkitt's lymphoma cell line versus human granulocytic progenitor cells: rescue by folinic acid and nucleosides.
Fabre I; Fabre G; Cano JP
Eur J Cancer Clin Oncol; 1986 Oct; 22(10):1247-54. PubMed ID: 3493143
[TBL] [Abstract][Full Text] [Related]
36. A comparison of the effects of nine folate analogs on early and late murine hematopoietic progenitor cells in vitro.
Strømhaug A; Warren DJ
Cancer Chemother Pharmacol; 2000; 45(6):450-6. PubMed ID: 10854131
[TBL] [Abstract][Full Text] [Related]
37. 5,10-Dideaza-5,6,7,8-tetrahydrofolic acid (DDATHF): a potent inhibitor of purine biosynthesis.
Nutr Rev; 1990 Nov; 48(11):421-3. PubMed ID: 2080047
[No Abstract] [Full Text] [Related]
38. Synthesis and biological activity of 7-oxo substituted analogues of 5-deaza-5,6,7,8-tetrahydrofolic acid (5-DATHF) and 5,10-dideaza-5,6,7,8-tetrahydrofolic acid (DDATHF).
Borrell JI; Teixidó J; Matallana JL; Martínez-Teipel B; Colominas C; Costa M; Balcells M; Schuler E; Castillo MJ
J Med Chem; 2001 Jul; 44(14):2366-9. PubMed ID: 11428931
[TBL] [Abstract][Full Text] [Related]
39. Impact of dietary folic acid on reduced folates in mouse plasma and tissues. Relationship to dideazatetrahydrofolate sensitivity.
Schmitz JC; Grindey GB; Schultz RM; Priest DG
Biochem Pharmacol; 1994 Jul; 48(2):319-25. PubMed ID: 8053927
[TBL] [Abstract][Full Text] [Related]
40. The 6S- and 6R-diastereomers of 5, 10-dideaza-5, 6, 7, 8-tetrahydrofolate are equiactive inhibitors of de novo purine synthesis.
Moran RG; Baldwin SW; Taylor EC; Shih C
J Biol Chem; 1989 Dec; 264(35):21047-51. PubMed ID: 2592365
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
